Gene Expression Signatures and the Spectrum of Coronary Artery Disease

Friede, Kevin A; Ginsburg, Geoffrey S.; Voora, Deepak

doi:10.1007/s12265-015-9640-6

Cited by 9 publications

(9 citation statements)

References 113 publications

(121 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AMI refers to myocardial necrosis induced by acute, persistent ischemia and hypoxia, which can result in further life-threatening complications, including arrhythmia, cardiogenic shock and acute heart failure. A previous study has demonstrated that changes in the expression of various genes (including ALOX5, MGST1, CREB5, IL1RN, CSF2R, VCAN are CSF3R) are correlated with susceptibility of patients to coronary heart disease ( 18 , 19 ). Furthermore, a previous study on the differential gene expression profile of AMI determined that the expression of ACSL1 in the peripheral blood of patients with AMI is significantly increased ( 11 ).…”

Section: Discussionmentioning

confidence: 99%

High expression of long chain acyl‑coenzyme A synthetaseï¿½1 in peripheral blood may be a molecular marker for assessing the risk of acute myocardial infarction

Yang

et al. 2017

Exp Ther Med

View full text Add to dashboard Cite

The current study aimed to investigate whether the increased expression of long chain acyl-coenzymeA synthetase 1 (ACSL1) in peripheral blood leukocytes (PBL) may be a molecular marker for the genetic evaluation of acute myocardial infarction (AMI). The mechanism of action of ACSL1 in the pathogenesis of AMI was also investigated. A total of 75 patients with AMI and 70 individuals without coronary heart disease were selected to participate in the present study. The demographic and clinical information of the enrolled subjects was recorded. Reverse transcription quantitative polymerase chain reaction and western blot analysis were applied to measure the expression of ACSL1 at the mRNA and protein levels. It was demonstrated that the expression of ACSL1 mRNA and protein in PBL was increased in patients with AMI compared with controls. Logistic regression analysis indicated that ACSL1 expression in PBL was an independent risk factor of AMI. There was a significant positive association between the level of ACSL1 expression and the degree of atherosclerosis in the coronary artery. Furthermore, patients with AMI exhibited an increased risk of atherosclerosis due to increased fasting blood glucose, total cholesterol, triglyceride and lipoprotein levels and decreased high-density lipoprotein levels, compared with controls. Therefore, the current study demonstrated that ACSL1 expression was increased in the PBLs of patients with AMI. The elevated expression of ACSL1 acts an independent risk factor of AMI and may act as a potential biomarker when determining the risk of AMI.

show abstract

Section: Discussionmentioning

confidence: 99%

High expression of long chain acyl‑coenzyme A synthetaseï¿½1 in peripheral blood may be a molecular marker for assessing the risk of acute myocardial infarction

Yang

et al. 2017

Exp Ther Med

View full text Add to dashboard Cite

show abstract

“…As we described previously [ 6 ], EV have an important role in the transport of circulating miRNAs. Several reports show the potential use of miRNAs in the diagnosis and prognosis of cardiac injury [ 3 , 7 , 8 , 43 – 47 ]. Yet, the temporal release profile of miRNAs upon cardiac injury is largely unexplored.…”

Section: Discussionmentioning

confidence: 99%

“…Increasing evidence suggests that circulating microRNAs (miRNA) can be potential biomarker candidates due to their highly specific elevation in blood upon stress, including MI [ 3 , 7 , 8 ]. MiRNAs are short (∼22 nucleotides) non-coding RNAs [ 9 ] that regulate gene expression at a post-transcriptional level [ 10 , 11 ].…”

Section: Introductionmentioning

confidence: 99%

Circulating Extracellular Vesicles Contain miRNAs and are Released as Early Biomarkers for Cardiac Injury

Deddens

Vrijsen

Colijn

et al. 2016

J. of Cardiovasc. Trans. Res.

View full text Add to dashboard Cite

Plasma-circulating microRNAs have been implicated as novel early biomarkers for myocardial infarction (MI) due to their high specificity for cardiac injury. For swift clinical translation of this potential biomarker, it is important to understand their temporal and spatial characteristics upon MI. Therefore, we studied the temporal release, potential source, and transportation of circulating miRNAs in different models of ischemia reperfusion (I/R) injury. We demonstrated that extracellular vesicles are released from the ischemic myocardium upon I/R injury. Moreover, we provided evidence that cardiac and muscle-specific miRNAs are transported by extracellular vesicles and are rapidly detectable in plasma. Since these vesicles are enriched for the released miRNAs and their detection precedes traditional damage markers, they hold great potential as specific early biomarkers for MI.Electronic supplementary materialThe online version of this article (doi:10.1007/s12265-016-9705-1) contains supplementary material, which is available to authorized users.

show abstract

“…However, the direct, clear-cut, and distinct causal relationship implicit in the concept of “a gene for…” most likely does not apply to complex cardiovascular maladies, such as various inherited cardiomyopathies (e.g., genetic HCM, DCM, restrictive cardiomyopathy, and arrhythmogenic right ventricular cardiomyopathy [64]), coronary artery disease, and heart failure [65]. The causal chain from genes to such maladies is probably long and encompasses many interconnected genes (dozens, hundreds, or even thousands; cf., Fig.…”

Section: Gene Mechanisms Operative In Determining Phenotypementioning

confidence: 99%

“…Such findings can begin the important process of elucidating how specific genes interact with each other and with environmental factors/exposures [2–5] to engender disease, and can provide new targets for treatment [65]. With the full sequence of the human genome in hand, NGS technologies have subsequently reduced the cost of DNA sequencing from approximately US$0.50 per kilobase (kb −1 ) to less than US$0.001 kb −1 and radically increased throughput by sequencing in a massively parallel fashion [66].…”

Section: Gene Mechanisms Operative In Determining Phenotypementioning

confidence: 99%

Linking Genes to Cardiovascular Diseases: Gene Action and Gene–Environment Interactions

Pasipoularides

2015

J. of Cardiovasc. Trans. Res.

121

View full text Add to dashboard Cite

A unique myocardial characteristic is its ability to grow/remodel in order to adapt; this is determined partly by genes and partly by the environment and the milieu intérieur. In the “post-genomic” era, a need is emerging to elucidate the physiologic functions of myocardial genes, as well as potential adaptive and maladaptive modulations induced by environmental/epigenetic factors. Genome sequencing and analysis advances have become exponential lately, with escalation of our knowledge concerning sometimes controversial genetic underpinnings of cardiovascular diseases. Current technologies can identify candidate genes variously involved in diverse normal/abnormal morphomechanical phenotypes, and offer insights into multiple genetic factors implicated in complex cardiovascular syndromes. The expression profiles of thousands of genes are regularly ascertained under diverse conditions. Global analyses of gene expression levels are useful for cataloging genes and correlated phenotypes, and for elucidating the role of genes in maladies. Comparative expression of gene networks coupled to complex disorders can contribute insights as to how “modifier genes” influence the expressed phenotypes. Increasingly, a more comprehensive and detailed systematic understanding of genetic abnormalities underlying, for example, various genetic cardiomyopathies is emerging. Implementing genomic findings in cardiology practice may well lead directly to better diagnosing and therapeutics. There is currently evolving a strong appreciation for the value of studying gene anomalies, and doing so in a non-disjointed, cohesive manner. However, it is challenging for many—practitioners and investigators—to comprehend, interpret, and utilize the clinically increasingly accessible and affordable cardiovascular genomics studies. This survey addresses the need for fundamental understanding in this vital area.

show abstract

Gene Expression Signatures and the Spectrum of Coronary Artery Disease

Cited by 9 publications

References 113 publications

High expression of long chain acyl‑coenzyme A synthetaseï¿½1 in peripheral blood may be a molecular marker for assessing the risk of acute myocardial infarction

High expression of long chain acyl‑coenzyme A synthetaseï¿½1 in peripheral blood may be a molecular marker for assessing the risk of acute myocardial infarction

Circulating Extracellular Vesicles Contain miRNAs and are Released as Early Biomarkers for Cardiac Injury

Linking Genes to Cardiovascular Diseases: Gene Action and Gene–Environment Interactions

Contact Info

Product

Resources

About